Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

571 articles

Showing 1–2 of 2 articles · Keyword: plasmid DNA Clear keyword

Molecular therapy. Nucleic acids2026ResearchNon-viral Gene DeliveryDrug Delivery

1. cGAS-mediated immunogenicity impairs the stability and safety of LNP-encapsulated DNA in vivo

Wang X, Liu T, Long B, Li M, Yao Y, Fu Y, Et Al.

DNA-based non-viral gene therapy offers a promising platform for titratable gain-of-function treatments, enabling multi-dosing and sustained efficacy. However, its clinical translation has been constrained by unintended immune activation. We systematically investigated the pathogenesis of DNA drug-induced toxicity in…

Read the article
Pharmaceutics2026ReviewNon-viral Gene DeliveryDrug Delivery

2. Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer

Anwer K, Sood S, Sparks J, Faller Dv, Limon A, Lindborg Sr

Interleukin-12 (IL-12) is a potent immunostimulatory cytokine with well-established antitumor activity, but systemic recombinant IL-12 administration has been constrained by inflammatory toxicity, high circulating cytokine peaks, and insufficient tumor-local exposure. IMNN-001 is a non-viral IL-12 gene therapy…

Read the article
Articles | Brilliant Blue Biosciences